Navigation Links
Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Date:10/29/2007

TORONTO, Oct. 29 /PRNewswire/ - Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved a targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment of an undisclosed amount.

Dalton Medicinal Chemistry Partners is utilizing their medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada) Ltd. Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to achieve this milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd. It is a pleasure working with the talented team at BI."

About Dalton

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients (API) at the gram or kilogram scale. Dalton carries out sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Bruker Daltonics and Bruker AXS Announce Merger Agreement
2. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
3. Alliance looks to create the right chemistry in SE Wisconsin
4. UW-Eau Claire chemistry faculty get $600,000 in NSF grants
5. Jellyfish partners for sales tracking technology
6. GE Healthcare partners with UNC on breast cancer imaging research
7. Manufacturing partnership will move into biotech and biomedical spaces
8. Fergus joins Baird Venture Partners, Caden Bio
9. Avolte Venture Partners reaches capital goal
10. NimbleGen partners with UK biotech firm
11. Big pharma seeks Wisconsin biotech partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... to announce that Mitsui & Co. Ltd., its partner ... acid plant, is investing an additional CDN$25 million in ... its stake from 30% to 40%.  Mitsui will also ... acid produced in Sarnia , providing ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... announced that it has joined the Human Vaccines Project, a public-private partnership ... and cancer. , The Human Vaccines Project brings together leading pharmaceutical ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, ... Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February ... than 100 tables for its annual event, which will run from 3:00 p.m. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Global Stem ... agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate Global ... in the latest adipose and bone marrow therapies. , Through the new ...
Breaking Biology Technology:
(Date:2/9/2016)... Mass., Feb. 9, 2016 Aware, Inc. (NASDAQ: AWRE ... financial results for its fourth quarter and year ended December 31, ... for the fourth quarter of 2015 was $6.9 million, an increase ... year. Operating income in the fourth quarter of 2015 was $2.6 ... --> --> Higher revenue ...
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
(Date:2/2/2016)... Feb. 2, 2016 This BCC Research ... market by reviewing the recent advances in high ... drive the field forward. Includes forecast through 2019. ... the challenges and opportunities that exist in the ... solution developers, as well as IT and bioinformatics ...
Breaking Biology News(10 mins):